ReviewCureus2026
Long-Term Neurodevelopmental Outcomes After Hypoxic-Ischemic Encephalopathy Treated With Therapeutic Hypothermia: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic hypothermia (TH) is the cornerstone of treatment for infants with moderate-to-severe hypoxic-ischemic encephalopathy (HIE). The long-term neurodevelopmental outcomes after 18 to 24 months and the persistence or onset of impairments throughout later childhood, however, are still up for discussion. This systematic review evaluates the long-term neurodevelopmental outcomes (≥18 months) of babies with moderate-to-severe HIE treated with TH. A comprehensive literature search of PubMed/Medical Literature Analysis and Retrieval System Online (MEDLINE), Scopus, Web of Science, and Cochrane Controlled Register of Trials (CENTRAL) yielded 213 records. Following duplicate removal and screening, 10 studies encompassing 1,134 neonates met eligibility criteria. Two reviewers independently extracted the data and performed a design-specific risk of bias assessment. Methodological quality was evaluated using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for cohort studies, the Quality in Prognosis Studies (QUIPS) tool for prognostic factor studies, and the Cochrane Risk of Bias 2 (RoB 2) tool for randomized trials. Across the included studies, 52%-81% of survivors treated with therapeutic hypothermia achieved normal or mildly abnormal neurodevelopment at 18-36 months, with mortality ranging from 3.8% to 19.6%. Consistent predictors of adverse outcomes included delayed cooling, elevated lactate, severe EEG abnormalities, rewarming seizures, abnormal MRI, and prolonged birth depression. Novel biomarkers showed prognostic promise but require validation. Outcomes in low- and middle-income countries (LMICs) were variable, with high attrition limiting generalisability, and evidence suggested that impairments may emerge at school age, supporting surveillance beyond 24 months. TH is associated with positive long-term outcomes for the majority of survivors with moderate-to-severe HIE. However, neurodevelopmental impairments may emerge or persist into school age, necessitating surveillance beyond 24 months. While TH is effective in high-income settings, its benefits in LMICs depend on adequate resources and follow-up infrastructure. Validation of novel biomarkers and standardization of outcome measures are priorities for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.